The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).
 
April A. N. Rose
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Consulting or Advisory Role - Pfizer
 
Olubukola Ayodele
No Relationships to Disclose
 
Sofia Genta
No Relationships to Disclose
 
Thiago Pimentel Muniz
No Relationships to Disclose
 
Deirdre Kelly
No Relationships to Disclose
 
Kelsey Hodgson
No Relationships to Disclose
 
Ian King
Consulting or Advisory Role - Agendia; Bristol-Myers Squibb
 
Tracy Stockley
No Relationships to Disclose
 
Trevor J. Pugh
No Relationships to Disclose
 
Zaid Saeed Kamil
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; Iovance Biotherapeutics; LaRoche Posay; Merck; Novartis; Sanofi; Sun Pharma
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst)
 
Natasha B. Leighl
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Xcovery
Research Funding - EMD Serono (Inst); Guardant Health (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Nektar; Roche
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Pfizer; Roche/Genentech
 
Aaron Richard Hansen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Samuel Saibil
Consulting or Advisory Role - Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
David W. Cescon
Consulting or Advisory Role - Agendia; AstraZeneca; Exact Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche/Genentech
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending - Biomarkers of TTK inhibitors (assigned to institution)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janpix; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Relay Therapeutics; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche